These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30653559)

  • 1. Molecular features of premenopausal breast cancers in Latin American women: Pilot results from the PRECAMA study.
    Olivier M; Bouaoun L; Villar S; Robitaille A; Cahais V; Heguy A; Byrnes G; Le Calvez-Kelm F; Torres-Mejía G; Alvarado-Cabrero I; Imani-Razavi FS; Inés Sánchez G; Jaramillo R; Porras C; Rodriguez AC; Garmendia ML; Soto JL; Romieu I; Porter P; Guenthoer J; Rinaldi S;
    PLoS One; 2019; 14(1):e0210372. PubMed ID: 30653559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
    Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
    Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
    Li G; Guo X; Chen M; Tang L; Jiang H; Day JX; Xie Y; Peng L; Xu X; Li J; Wang S; Xiao Z; Dai L; Wang J
    PLoS One; 2018; 13(9):e0203495. PubMed ID: 30212483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
    Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
    Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world Comparison of P53 Immunohistochemistry and TP53 Mutation Analysis Using Next-generation Sequencing.
    Lee H; Cho YA; Kim DG; Son JY; Cho EY
    Anticancer Res; 2024 Sep; 44(9):3983-3994. PubMed ID: 39197898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.
    Guerini-Rocco E; Hodi Z; Piscuoglio S; Ng CK; Rakha EA; Schultheis AM; Marchiò C; da Cruz Paula A; De Filippo MR; Martelotto LG; De Mattos-Arruda L; Edelweiss M; Jungbluth AA; Fusco N; Norton L; Weigelt B; Ellis IO; Reis-Filho JS
    J Pathol; 2015 Oct; 237(2):166-78. PubMed ID: 26011570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.
    Manoharan V; Karunanayake EH; Tennekoon KH; De Silva S; Imthikab AIA; De Silva K; Angunawela P; Vishwakula S; Lunec J
    BMC Cancer; 2020 Jan; 20(1):72. PubMed ID: 32000721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
    Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
    Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reproductive factors and molecular subtypes of breast cancer among premenopausal women in Latin America: the PRECAMA study.
    Romieu I; Biessy C; Carayol M; His M; Torres-Mejía G; Ángeles-Llerenas A; Sánchez GI; Jaramillo R; Navarro E; Porras C; Ocampo R; Rodriguez AC; Garmendia ML; Bustamante E; Olivier M; Porter P; Rinaldi S;
    Sci Rep; 2018 Aug; 8(1):13109. PubMed ID: 30166604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 protein expression patterns associated with TP53 mutations in breast carcinoma.
    Anderson SA; Bartow BB; Harada S; Siegal GP; Wei S; Dal Zotto VL; Huang X
    Breast Cancer Res Treat; 2024 Aug; 207(1):213-222. PubMed ID: 38900212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted sequencing reveals the somatic mutation landscape in a Swedish breast cancer cohort.
    Mathioudaki A; Ljungström V; Melin M; Arendt ML; Nordin J; Karlsson Å; Murén E; Saksena P; Meadows JRS; Marinescu VD; Sjöblom T; Lindblad-Toh K
    Sci Rep; 2020 Nov; 10(1):19304. PubMed ID: 33168853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.
    Silwal-Pandit L; Vollan HK; Chin SF; Rueda OM; McKinney S; Osako T; Quigley DA; Kristensen VN; Aparicio S; Børresen-Dale AL; Caldas C; Langerød A
    Clin Cancer Res; 2014 Jul; 20(13):3569-80. PubMed ID: 24803582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].
    Park JH; Ahn JH; Kim JE; Jung KH; Gong G; Lee HJ; Son BH; Ahn SH; Kim HH; Shin HJ; Moon DH; Kim D; Kim SB
    Anticancer Res; 2020 Oct; 40(10):5883-5893. PubMed ID: 32988919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
    Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
    Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole exome sequencing of rare aggressive breast cancer histologies.
    Dieci MV; Smutná V; Scott V; Yin G; Xu R; Vielh P; Mathieu MC; Vicier C; Laporte M; Drusch F; Guarneri V; Conte P; Delaloge S; Lacroix L; Fromigué O; André F; Lefebvre C
    Breast Cancer Res Treat; 2016 Feb; 156(1):21-32. PubMed ID: 26907767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
    Lee S; Kim HY; Jung YJ; Jung CS; Im D; Kim JY; Lee SM; Oh SH
    Curr Probl Cancer; 2022 Apr; 46(2):100843. PubMed ID: 35180531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.
    Guerini-Rocco E; Piscuoglio S; Ng CK; Geyer FC; De Filippo MR; Eberle CA; Akram M; Fusco N; Ichihara S; Sakr RA; Yatabe Y; Vincent-Salomon A; Rakha EA; Ellis IO; Wen YH; Weigelt B; Schnitt SJ; Reis-Filho JS
    J Pathol; 2016 Apr; 238(5):677-88. PubMed ID: 26806567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing.
    Jia M; Liao N; Chen B; Zhang G; Wang Y; Li X; Cao L; Mok H; Ren C; Li K; Li C; Wen L; Lin J; Wei G; Balch CM
    Breast Cancer; 2021 May; 28(3):644-652. PubMed ID: 33386585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing.
    Roy-Chowdhuri S; de Melo Gagliato D; Routbort MJ; Patel KP; Singh RR; Broaddus R; Lazar AJ; Sahin A; Alvarez RH; Moulder S; Wheler JJ; Janku F; Gonzalez-Angulo AM; Chavez-MacGregor M; Valero V; Ueno NT; Mills G; Mendelsohn J; Yao H; Aldape K; Luthra R; Meric-Bernstam F
    Am J Clin Pathol; 2015 Nov; 144(5):713-21. PubMed ID: 26486734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discordance of PIK3CA and TP53 mutations between breast cancer brain metastases and matched primary tumors.
    Thulin A; Andersson C; Werner Rönnerman E; De Lara S; Chamalidou C; Schoenfeld A; Kovács A; Fagman H; Enlund F; Linderholm BK
    Sci Rep; 2021 Dec; 11(1):23548. PubMed ID: 34876602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.